Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Work In Process (2017 - 2024)

China Pharma Holdings' Work In Process history spans 8 years, with the latest figure at $334430.0 for Q3 2024.

  • For Q3 2024, Work In Process fell 50.59% year-over-year to $334430.0; the TTM value through Sep 2024 reached $334430.0, down 50.59%, while the annual FY2023 figure was $413597.0, 25.77% down from the prior year.
  • Work In Process reached $334430.0 in Q3 2024 per CPHI's latest filing, up from $87308.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $676885.0 in Q3 2023 to a low of $87308.0 in Q2 2024.
  • Average Work In Process over 5 years is $431457.2, with a median of $423493.0 recorded in 2020.
  • Peak YoY movement for Work In Process: soared 110.99% in 2020, then crashed 76.07% in 2024.
  • A 5-year view of Work In Process shows it stood at $662999.0 in 2020, then decreased by 15.97% to $557146.0 in 2021, then changed by 0.0% to $557146.0 in 2022, then dropped by 25.77% to $413597.0 in 2023, then fell by 19.14% to $334430.0 in 2024.
  • Per Business Quant, the three most recent readings for CPHI's Work In Process are $334430.0 (Q3 2024), $87308.0 (Q2 2024), and $242726.0 (Q1 2024).